Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul;346(1):11–22. doi: 10.1124/jpet.113.203984

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

PMC Copyright notice

Fig. 6. — Effects of NOP and MOP antagonists on antiallodynic effects of intrathecal SCH221510 (10 µg) and morphine (10 µg) in neuropathic pain. Antagonists were administered intrathecally 10 minutes before SCH221510 or morphine. Changes in SCH221510-induced increase in the paw withdrawal thresholds (A) and the percentage of maximum possible antiallodynic effect (B) after J-113397, naltrexone, or vehicle pretreatment at 0.5 hours after intrathecal SCH221510. Right panels: changes in morphine-induced increase in the paw withdrawal thresholds (B) and the percentage of maximum possible antiallodynic effect (D) after naltrexone, J-113397, or vehicle pretreatment at 0.5 hours after intrathecal morphine. *Statistically significant difference from the vehicle control (P < 0.05).